NPI 1851312243 — Billing Profile & Reimbursement Data
NPI 1851312243 · XX · healthcare
Customize your policy alerts
Sign up for NPI 1851312243 — Billing Profile & Reimbursement Data policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
NPI 1851312243 is a healthcare provider located in Unspecified Location. This profile covers 45 Medicare and 0 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services. Note: "XX" is a placeholder CMS uses when a provider's practice-location state wasn't reported — not a traditional US state; claims coded under it are grouped and benchmarked here the same way a traditional state would be.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | NPI 1851312243 |
| Address | |
| City | |
| State | XX (Unspecified Location) |
| ZIP | |
| Taxonomy | N/A |
| NPI Enumerated | |
| NPI Deactivated | May 15, 2026 |
(source: CMS Medicare & Medicaid claims data)
Medicare: Total Revenue Breakdown by CPT/HCPCS Code
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
Medicare: Complete Services Breakdown
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
45 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12,050 | $30 | $409.7K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 8,060 | $30 | $209.6K |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 16,040 | $10 | $160.4K |
| J3262 | Injection, tocilizumab, 1 mg | 24,080 | $10 | $120.4K |
| J0897 | Injection, denosumab, 1 mg | 5,220 | $20 | $94K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 580 | $90 | $51.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 500 | $100 | $49.1K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 260 | $60 | $14.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 130 | $60 | $8K |
| 86481 | The lab analyst performs a test to evaluate an antigen response to certain tuberculosis (TB) antibodies by enumerating T cells that produce gamma interferon. | 50 | $100 | $4.4K |
Showing 1–10 of 45
Medicare: Competitive Analysis & Benchmarks
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes. Note: this provider's state, "XX," is a placeholder CMS uses when a provider's practice-location state wasn't reported — not a traditional US state; the State panel below benchmarks against other providers coded under the same designation.
View: State1 / 2
Full comparison — all codes billed, vs. state median
45 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 96413 | 20 | 10 | 350 | $100 | $34.2K |
| J0897 | 79 | 10 | 1,440 | $20 | $26.6K |
| 99213 | 4,701 | 10 | 140 | $60 | $18.8K |
| 99214 | 1,143 | 10 | 80 | $90 | $15.8K |
| 85025 | 284 | 10 | 820 | $10 | $6.2K |
| 36415 | 640 | 10 | 230 | $10 | $5.5K |
| 96365 | 233 | 10 | 90 | $50 | $4.2K |
| 96372 | 2,579 | 10 | 400 | $10 | $4.1K |
| 96415 | 64 | 10 | 150 | $20 | $3.2K |
| 77080 | 258 | 10 | 310 | $10 | $3K |
Showing 1–10 of 45
Frequently Asked Questions
References
- 1.Medicare Physician & Other Practitioner by Provider and Service. CMS.gov.Provider-level Medicare Part B utilization and payment data.
- 2.NPPES NPI Registry. CMS.gov.National Provider Identifier registry used for provider enumeration and taxonomy metadata.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.